The Risk of Ischaemic Colitis in Irritable Bowel Syndrome Patients Treated with Serotonergic Therapies

Author： Lewis James H.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.34, Iss.7, 2011-07, pp. : 545-565

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Serotonergic modulation and irritable bowel syndrome

By Borman R.  

Expert Opinion on Emerging Drugs, Vol. 6, Iss. 1, 2001-04 ,pp. : 57-68

Informa Healthcare

Access to resources Recommend Favorite

Existing and emerging therapies for irritable bowel syndrome

By Acosta Ruben D   Cash Brooks D  

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 2, 2011-06 ,pp. : 389-402

Informa Healthcare

Access to resources Recommend Favorite

Novel therapies in the treatment of irritable bowel syndrome

By Berrada Driss   Lembo Tony  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 4, 2003-04 ,pp. : 635-645

Informa Healthcare

Access to resources Recommend Favorite

Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea

By Chey William D   Cash Brooks D  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 2, 2005-02 ,pp. : 185-193

Informa Healthcare

Access to resources Recommend Favorite

Benefit-Risk Assessment of Tegaserod in Irritable Bowel Syndrome

By Lea R.   Whorwell P.J.  

Drug Safety, Vol. 27, Iss. 4, 2004-01 ,pp. : 229-242

Adis International

Access to resources Recommend Favorite